HK1201738A1 - Dabigatran amidoxime acid esters as prodrugs and use thereof as pharmaceuticals - Google Patents

Dabigatran amidoxime acid esters as prodrugs and use thereof as pharmaceuticals

Info

Publication number
HK1201738A1
HK1201738A1 HK15102313.9A HK15102313A HK1201738A1 HK 1201738 A1 HK1201738 A1 HK 1201738A1 HK 15102313 A HK15102313 A HK 15102313A HK 1201738 A1 HK1201738 A1 HK 1201738A1
Authority
HK
Hong Kong
Prior art keywords
dabigatran
prodrugs
pharmaceuticals
acid esters
amidoxime
Prior art date
Application number
HK15102313.9A
Other languages
English (en)
Chinese (zh)
Inventor
Bernd Clement
Juerke Kotthaus
Joscha Kotthaus
Dennis Schade
Original Assignee
Dritte Patentportfolio Beteili
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteili filed Critical Dritte Patentportfolio Beteili
Publication of HK1201738A1 publication Critical patent/HK1201738A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15102313.9A 2011-07-25 2015-03-06 Dabigatran amidoxime acid esters as prodrugs and use thereof as pharmaceuticals HK1201738A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11175230.9A EP2550966B1 (de) 2011-07-25 2011-07-25 Dabigatran-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel
PCT/EP2012/063071 WO2013013946A1 (de) 2011-07-25 2012-07-05 Dabigatran-amidoximsäureesters als prodrugs und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
HK1201738A1 true HK1201738A1 (en) 2015-09-11

Family

ID=46466528

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102313.9A HK1201738A1 (en) 2011-07-25 2015-03-06 Dabigatran amidoxime acid esters as prodrugs and use thereof as pharmaceuticals

Country Status (20)

Country Link
US (1) US8853245B2 (es)
EP (2) EP2550966B1 (es)
JP (1) JP2014521619A (es)
KR (1) KR20140049021A (es)
CN (1) CN103945845A (es)
AU (1) AU2012289112B2 (es)
BR (1) BR112014001970A2 (es)
CA (1) CA2842304A1 (es)
CY (1) CY1118294T1 (es)
DK (1) DK2550966T3 (es)
ES (1) ES2611610T3 (es)
HK (1) HK1201738A1 (es)
HR (1) HRP20161675T1 (es)
HU (1) HUE032862T2 (es)
LT (1) LT2550966T (es)
PL (1) PL2550966T3 (es)
PT (1) PT2550966T (es)
RU (1) RU2014106866A (es)
SI (1) SI2550966T1 (es)
WO (1) WO2013013946A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040045742A1 (en) * 2001-04-10 2004-03-11 Halliburton Energy Services, Inc. Force-balanced roller-cone bits, systems, drilling methods, and design methods
WO2016019846A1 (zh) * 2014-08-06 2016-02-11 四川海思科制药有限公司 一种达比加群酯衍生物及其制备方法和在药学上的用途
WO2016019848A1 (zh) * 2014-08-06 2016-02-11 四川海思科制药有限公司 一种达比加群硫酯衍生物及其制备方法和在药学上的用途
DE102016102887A1 (de) * 2016-02-18 2017-08-24 Develco Pharma Schweiz Ag Orale Darreichungsform eines Dabigatran-Prodrugs zur Behandlung von Krankheiten
CN110448557A (zh) * 2019-09-05 2019-11-15 黄筱茜 抗凝血药达比加群酯的新药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10235639A1 (de) 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10341043A1 (de) 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
CA2657269A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
DE102008007440A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Aminosäurederivate als Arzneistoffe
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
NZ592615A (en) * 2008-11-11 2013-06-28 Boehringer Ingelheim Int Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
KR20110082563A (ko) * 2008-11-11 2011-07-19 베링거 인겔하임 인터내셔날 게엠베하 통상의 와파린 요법에 비해 효능이 향상된 다비가트란 에텍실레이트 또는 이의 염을 사용하여 혈전증을 치료하거나 예방하는 방법
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen

Also Published As

Publication number Publication date
US8853245B2 (en) 2014-10-07
EP2773347B1 (de) 2017-09-13
WO2013013946A1 (de) 2013-01-31
BR112014001970A2 (pt) 2017-02-21
US20130030023A1 (en) 2013-01-31
EP2550966A1 (de) 2013-01-30
PL2550966T3 (pl) 2017-03-31
PT2550966T (pt) 2017-01-31
SI2550966T1 (sl) 2017-01-31
AU2012289112B2 (en) 2017-01-05
LT2550966T (lt) 2017-01-25
CA2842304A1 (en) 2013-01-31
CN103945845A (zh) 2014-07-23
EP2773347A1 (de) 2014-09-10
AU2012289112A1 (en) 2014-02-13
ES2611610T3 (es) 2017-05-09
KR20140049021A (ko) 2014-04-24
RU2014106866A (ru) 2015-08-27
DK2550966T3 (en) 2017-02-06
HRP20161675T1 (hr) 2017-02-24
JP2014521619A (ja) 2014-08-28
EP2550966B1 (de) 2016-10-19
CY1118294T1 (el) 2017-06-28
HUE032862T2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
IL276012B (en) Pharmaceutical preparations containing sorbitan esters
IL249227A0 (en) Process for preparing 4)-n-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetamidic acid ethyl ester
HK1201122A1 (en) 6-amino-2-substituted-5-vinylsilylpyrimidine-4-carboxylic acids and esters and 4-amino-6-substituted-3-vinylsilylpyridine-2-carboxylic acids and esters as herbicides 6--2--5--4- 4-- 6--3--2-
SG11201503646TA (en) Esterification of 2,5-furan-dicarboxylic acid
IL233413A0 (en) Methods for producing fincol esters of 4-chloro-2-fluoro-3-converted-phenylboronic acid and methods for using them
HK1194360A1 (zh) 生產丙烯酸和丙烯酸酯的方法
IL250370A0 (en) Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals
IL249825A0 (en) Propionic acid derivatives converted in 3-heteroylamino and their use in pharmaceutical preparations
HK1201738A1 (en) Dabigatran amidoxime acid esters as prodrugs and use thereof as pharmaceuticals
RS55954B1 (sr) Postupci za proizvodnju akrilnih kiselina i akrilata
RS55557B1 (sr) Amidoksimski estri karboksilnih kiselina pentamidina kao prolekovi i njihova primena kao lekova
TH148772B (th) กรรมวิธีสำหรับการเตรียมกรดเมแธคริลิคและเอสเทอร์ของกรดเมแธคริลิค